As part of the Food and Drug Administration’s continued commitment to improve communication about risks posed by prescription medications, its Center for Drug Evaluation and Research (CDER) is holding a public meeting today to evaluate current practices and to explore new tools and strategic partnerships to enhance future efforts.
“In the past year we have made significant strides in alerting healthcare professionals and their patients of emerging risks associated with prescription medications,” said Andrew von Eschenbach, MD, Acting FDA Commissioner. “We intend to use the public feedback we receive at this meeting to advance our understanding of the effectiveness of our current efforts and to develop new tools to hone our ability to inform the public.”
